Javascript must be enabled to continue!
Analgesic and adverse effects of a fixed-ratio morphine-oxycodone combination (MoxDuo®) in the treatment of postoperative pain
View through CrossRef
Objective: To compare efficacy and safety profiles of an immediate-release morphine and oxycodone Dual-Opioid® combination (MoxDuo®) versus its individual components and versus its morphine-equivalent doses in moderate to severe postoperative pain patients.Design: Randomized, double-blind, 48-hour, parallel-treatment, multicenter, six-arm study of MoxDuo.Setting: Six US centers.Patients: Within 6 hours after bunionectomy surgery, patients were eligible if they reported pain intensity 2 on the 4-point Likert scale and 4 on an 11-point Numerical Pain Rating Scale (197 randomly assigned; 175 completers).Interventions: MoxDuo 12 mg/8 mg, MoxDuo 6 mg/4 mg, morphine 12 mg, oxycodone 8 mg, morphine 6 mg, or oxycodone 4 mg (all administered q6h).Main outcome measure: Sum of pain intensity differences 0-24 hours after the first dose of study medication (SPID24) and percentage of patients with moderate to severe nausea, emesis, or dizziness.Results: SPID24 was significantly better in the MoxDuo 12 mg/8 mg group when compared with its individual components (morphine 12 mg [p = 0.009] and oxycodone 8 mg [p = 0.037]), and when compared with MoxDuo 6 mg/4 mg (p = 0.011; 54.3 vs 28.5, 35.7, and 30.0, respectively). MoxDuo 6 mg/4 mg and its morphine-equivalent doses (morphine 12 mg and oxycodone 8 mg) had comparable analgesic effects. There was a 50-75 percent reduction in moderate to severe adverse events (AEs) commonly associated with opioids (ie, nausea, vomiting, and dizziness) in the MoxDuo 6 mg/4 mg group when compared with its morphineequivalent dose groups.Conclusions: MoxDuo produced superior analgesic effects when compared with its individual components, but comparable efficacy when compared with its morphine-equivalent doses. Common AEs were reduced at least 50 percent with MoxDuo when compared with its morphine-equivalent doses. MoxDuo may be an improved intervention in the management of moderate to severe acute pain.
Weston Medical Publishing
Title: Analgesic and adverse effects of a fixed-ratio morphine-oxycodone combination (MoxDuo®) in the treatment of postoperative pain
Description:
Objective: To compare efficacy and safety profiles of an immediate-release morphine and oxycodone Dual-Opioid® combination (MoxDuo®) versus its individual components and versus its morphine-equivalent doses in moderate to severe postoperative pain patients.
Design: Randomized, double-blind, 48-hour, parallel-treatment, multicenter, six-arm study of MoxDuo.
Setting: Six US centers.
Patients: Within 6 hours after bunionectomy surgery, patients were eligible if they reported pain intensity 2 on the 4-point Likert scale and 4 on an 11-point Numerical Pain Rating Scale (197 randomly assigned; 175 completers).
Interventions: MoxDuo 12 mg/8 mg, MoxDuo 6 mg/4 mg, morphine 12 mg, oxycodone 8 mg, morphine 6 mg, or oxycodone 4 mg (all administered q6h).
Main outcome measure: Sum of pain intensity differences 0-24 hours after the first dose of study medication (SPID24) and percentage of patients with moderate to severe nausea, emesis, or dizziness.
Results: SPID24 was significantly better in the MoxDuo 12 mg/8 mg group when compared with its individual components (morphine 12 mg [p = 0.
009] and oxycodone 8 mg [p = 0.
037]), and when compared with MoxDuo 6 mg/4 mg (p = 0.
011; 54.
3 vs 28.
5, 35.
7, and 30.
0, respectively).
MoxDuo 6 mg/4 mg and its morphine-equivalent doses (morphine 12 mg and oxycodone 8 mg) had comparable analgesic effects.
There was a 50-75 percent reduction in moderate to severe adverse events (AEs) commonly associated with opioids (ie, nausea, vomiting, and dizziness) in the MoxDuo 6 mg/4 mg group when compared with its morphineequivalent dose groups.
Conclusions: MoxDuo produced superior analgesic effects when compared with its individual components, but comparable efficacy when compared with its morphine-equivalent doses.
Common AEs were reduced at least 50 percent with MoxDuo when compared with its morphine-equivalent doses.
MoxDuo may be an improved intervention in the management of moderate to severe acute pain.
Related Results
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
PERBANDINGAN SKALA NYERI PASIEN PASCA OPERASI SEKSIO SESAREA YANG DIBERIKAN MORFIN INTRATEKAL DENGAN MORFIN INTRATEKAL DITAMBAH KETOROLAK INTRA
PERBANDINGAN SKALA NYERI PASIEN PASCA OPERASI SEKSIO SESAREA YANG DIBERIKAN MORFIN INTRATEKAL DENGAN MORFIN INTRATEKAL DITAMBAH KETOROLAK INTRA
Abstract: Caesarean section is one of the most common procedures performed. It is estimated that 15% of births worldwide and 21.1% of those in developed countries occur via cesarea...
Clinical pharmacology of morphine in infants and children
Clinical pharmacology of morphine in infants and children
Morphine is used to treat pain, for treatment of opioid dependence, and neonatal abstinence syndrome. Morphine is modestly absorbed from the gastrointestinal tract whereas after re...
Double‐Blind, Randomized Comparison of the Analgesic and Pharmacokinetic Profiles of Controlled‐ and Immediate‐Release Oral Oxycodone in Cancer Pain Patients
Double‐Blind, Randomized Comparison of the Analgesic and Pharmacokinetic Profiles of Controlled‐ and Immediate‐Release Oral Oxycodone in Cancer Pain Patients
Thirty patients with cancer pain completed a double‐blind crossover study comparing controlled‐release (CR) and immediate‐release (IR) oxycodone. In open‐label titration (2 to 21 d...
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Abstract
Thoracic outlet syndrome (TOS) is a complex and often overlooked condition caused by the compression of neurovascular structures as they pass through the thoracic outlet. ...
Efficacy and tolerability of oral morphine versus oxycodone/acetaminophen for analgesia in the emergency department
Efficacy and tolerability of oral morphine versus oxycodone/acetaminophen for analgesia in the emergency department
Objective: Oxycodone/acetaminophen is one of the most commonly prescribed medications for pain management in the emergency department (ED) despite its high abuse liability. Our obj...
Monitoring oxycodone use in patients with chronic pain: Analysis of oxycodone and metabolite excretion in saliva and urine
Monitoring oxycodone use in patients with chronic pain: Analysis of oxycodone and metabolite excretion in saliva and urine
Objective: Saliva is purported to have a close correspondence to plasma concentrations due to a passive diffusion process from plasma to saliva. However, limited data are available...
Acute Opioid Administration Undermines Recovery after SCI: Adverse Effects Are Not Restricted to Morphine
Acute Opioid Administration Undermines Recovery after SCI: Adverse Effects Are Not Restricted to Morphine
Previous studies have shown that administration of high doses of morphine in the acute phase of spinal cord injury (SCI) significantly undermines locomotor recovery and increases s...

